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Abstract
We report on a focused workshop of The Leukemia and Lymphoma Society that was held at
Goldsmiths, University of London in 2008. During this workshop we discussed new clinical and
experimental data in chronic myeloid leukemia (CML) research, particularly focusing on the
validity (or otherwise) of corresponding mathematical models and simulations. We were
specifically interested in whether the models could shed light on any of the fundamental
mechanisms underlying this disease. Moreover, we were aiming to form a new community of
clinicians and modelers looking at this disease and to define a common language and theoretical
framework within which collaboration could flourish.
The workshop showed the role that models can play, not just in trying to fit to existing data or
predicting what individual mechanisms or system behaviors might occur, but also in challenging
the orthodoxy of the concept of a stem cell and concepts such as “differentiation” and
“determination”. For years the prevailing view of a stem cell has been an entity (object) with a
fixed set of behaviors and with a pre-determined fate. New perspectives in modeling, coupled with
the new data that are being accumulated in the genesis of CML and its treatment, questions these
assumptions. We propose how we can reach a consensus about a functional view of stem cells in a
more continuous and flexible way and how, within this context, we can investigate the
significance of modeling results and how they might impact on our interpretation of experimental
observations and the development of new clinical strategies.
This paper reports on the workshop and the state-of-the-art models and data from experimental
and clinical trials, and sets out a roadmap for more interdisciplinary collaboration between
modelers, wet-lab experimentalists, and clinicians interested in CML. It is our strong belief that a
more integrated and coherent interdisciplinary approach will further advance the treatment of
CML in future years.
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Introduction
During the last decade our increased knowledge of molecular mechanisms underlying the
pathogenesis of many types of cancers provides the basis for new therapeutic strategies. One
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prominent example for the successful application of specifically designed compounds that
interfere with signaling pathways controlling the survival and proliferation of malignant
cells is the treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitors
(TKI), imatinib mesylate (imatinib) and second generation agents, dasatinib and nilotinib
[1-4]. Such treatments, targeted at the oncoprotein causing the disease, allow for specific
inhibition of malignant cells, while largely sparing normal cells. Although the introduction
of imatinib as the frontline therapy for CML led to a dramatic improvement in therapy
compared to previous treatment options, there are a number of questions that remain. From a
clinical perspective the major problems are the persistence of residual disease and the
occurrence of TKI resistance [5-8]). Additionally, there are a number of conceptual
questions that cannot be answered. For example, although many details of the molecular
properties of the TKI molecules are known, the resulting systemic effects – the regulatory
responses at the cell population level – still remain unclear. To tackle these problems,
mathematical modeling and simulation studies provide powerful complementary approaches
(e.g. [9-11]). Such techniques, which are sometimes summarized under the term systems
biology, can enable a comprehensive understanding of regulatory mechanisms and the
resulting treatment effects. Moreover, we are at the stage where we can propose possible
mechanisms at the cell or tissue level that may result in the systems effects that are
observed.
To discuss the potential of mathematical and computational approaches in leukemia
research, a Focused Workshop of the Leukemia and Lymphoma Society entitled Stem Cells
and Leukemia — Concepts, Models, Simulations was held from April 24th – 26th at
Goldsmiths College, University of London. In total 24 scientists from Australia, France,
Germany, Switzerland, the United States and the United Kingdom attended the three day
meeting. It was the central aim of this workshop to bring together theoreticians,
experimentalists, and clinicians to discuss the application of theoretical methods for
achieving a better understanding of leukemic stem cells (LSCs) and to propose methods to
optimize leukemia treatments with the particular focus on CML. In particular, the workshop
was intended (1) to communicate the potential and the limitations of theoretical methods in
the context of experimental and clinical research, (2) to outline what requirements models
need in order to be accepted by clinicians/experimentalists, and (3) to identify clinical and
experimental problems that could benefit from the application of mathematical models. An
important aspect of the workshop was the participation of scientists who had a clinical
background (one-third of the attendees), demonstrating the growing recognition of the value
that the systems biology approach can bring to clinical research.
In this paper we will report on the major discussions of the workshop outlining where there
was consensus and where there was disagreement. As the key goal of this workshop was to
bring mathematical and computational modeling more into the mainstream of leukemia
research, the final chapter will provide a road map of how we can best bring about a more
coherent and focused collective effort in understanding CML.
Towards a consensus view on hematopoietic stem cells (HSCs)
A critical presumption for a successful conceptual discussion on stem cell disorders, such as
CML, is an agreement on what constitutes a stem cell. In this section we outline our (in the
main) consensus view on stem cells but also discuss where there were issues of
disagreement or lack of clarity with definitions and concepts.
Identifying stem cells
There is a broad consensus that functional testing is the hallmark characterization of tissue
stem cells in general and HSCs in particular. Although there are a number of sophisticated
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purification and enrichment protocols available [12-15]), there are no techniques as yet to
allow for a prospective identification of stem cells at the single cell level. Furthermore, until
now there are no validated phenotypic or genomic signatures that can unequivocally
characterize HSCs. In other words, the only way to determine whether a particular cell is a
HSC or not, is to challenge its cellular function in a specific assay system. The most
rigorous of these assays for HSC is the in vivo repopulation of irradiated mice using
transplantation. In these experiments, if the criteria of long-term reconstitution and
maintenance of functional tissue (i.e., multipotent differentiation capacity) including the re-
establishment and maintenance of a population of cells with (secondary) repopulating
potential (i.e., self-renewal capacity) have been fulfilled, then we have demonstrated that at
least one HSC was contained in the transplanted cells. Even more, if only one individual cell
had been transplanted with the same result, one could then conclude with certainty that this
particular transplanted cell was a HSC.
Uncertainty of stem cell characterization
There are some unavoidable problems with a functional definition. First, the assay gives
only a definite result if positive stem cell activity is observed. In the situation where a
negative assay results (i.e., where there is no long-term reconstitution), the question as to
whether the transplanted cells did not have stem cell potential or whether they simply did
not use it for whatever reason, cannot be answered. Secondly, even when what we see is a
positive repopulation assay and can demonstrate that HSCs must have existed in our original
population, it does not allow for a prospective identification of those cells. The original cells
have to actively respond to the assay system in order to demonstrate their stem cell potential
and, therefore, ultimately change their characteristics. That means, the test systems itself
changes the object to be tested. Although not identical, this type of uncertainty has
something in common with Heisenberg’s Uncertainty Principle in quantum physics [16], an
analogy that was introduced into stem cell biology almost two decades ago [17]. This type
of system intrinsic uncertainty is not the same as statistical uncertainty; it cannot be
eliminated by increasing sample sizes of experiments. However, even though a prospective
characterization of the stem cell potential of an individual cell is currently not possible, the
repeated assessment of the repopulating capacity of different subsets of cells from a certain
population will provide a guide to the heterogeneity of cell types, and their relative numbers,
within this population. As a result, it is possible to determine the probability of a randomly
chosen cell from a specified population to exhibit stem cell properties in a particular (assay)
system and, therefore, to obtain a measure of the average repopulation potential of this
population.
Stem cell potential and behavioral flexibility
Another consensus that was identified during the workshop is that a key feature of HSCs is
their ability to react flexibly to the current system needs. As a direct consequence, flexibility
in cellular action inevitably leads to asymmetries in cellular development. Please note, this
does not necessarily imply the existence of asymmetric cell division events (see below for a
more detailed discussion), it simply states that cell fate is determined by external as well as
internal factors.
Furthermore, if one acknowledges cellular flexibility as critical in defining what constitutes
a stem cell, or at least stem cell behavior, it is important to distinguish between the potential
of the cell to behave in a certain way and the actual behavior that is selected. If there are a
number of alternative behaviors that a cell may select, it must follow that there is always the
possibility that certain behaviors are not actually employed. The question then becomes
whether a definition of stem cells should be in terms of behavior or potential. Let us
consider this in more detail and choose between the two options:
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A cell is a stem cell if
1. it exhibits stem cell behavior.
2. it has the potential to exhibit stem cell behavior.
Option 1 results in us labeling only those cells as stem cells that exhibit stem cell behaviors
in a given, specific assay situation. Option 2, in contrast, implies that testing for stem cells
requires us to organize the whole range of potentially very different situations that might
induce latent capabilities to be activated. The key point to make here is that the stem cell
potential of an individual cell can never be determined with certainty, but only in a
probabilistic sense.
This distinction between potential and behavior may shed light on some controversial
disputes about stem cell “plasticity”. The question as to whether a certain tissue specific
(stem) cell has the general potential to contribute (by whatever mechanism) to other tissues
is considerably different from asking whether it does so in an unperturbed situation.
Challenging a specific potential might require artificial and potentially non-physiological
manipulations, which are not relevant under normal circumstances, potentially explaining
that these phenomena are hardly ever observed in unperturbed systems.
Heterogeneity of stem cell behavior
Both the potential of HSCs to behave in certain ways and the actual behaviors that are
observed clearly indicate that HSCs form a heterogeneous population. There was general
agreement amongst the workshop participants that heterogeneity of HSCs is an important
issue when discussing system dynamics both in terms of potential and behavior. Cellular
heterogeneity can be characterized by differences in the (genetically or epigenetically
determined) potentials of cells, but also by differences in the actual expression of these
potentials. As already mentioned, the flexible challenge of cellular functionalities results
from the different systemic needs, which are communicated through the different, local
environmental stimuli. Again there was complete agreement that it is the stem cell
supporting microenvironments, so called niches [18] which play a key role in determining
the fate of a stem cell with a given potential. And it would be naive to suppose that all
niches are homogenous and elicit the same behavior in all cells with the same potential.
Also, there is growing experimental evidence that there is not just one typical HSC niche but
rather different types of stem cell supporting contexts [19-23]. There were a number of
participants who believed that there is in fact a continuum of these niche milieus just like
there is a continuous range of potentials a cell can have. Also, whether a stem cell niche is
static or can change its cellular composition and/or functional capacities over time is
unclear.
The stem cell hierarchy dogma
HSCs and progenitor cells are classically considered to develop according to a
differentiation hierarchy that is characterized by a sequential and irreversible restriction of
the fate potential of individual cells [24-26]. This dogma, which is similarly depicted in
almost all text-books on HSCs, is still the prevailing view within the scientific community of
stem cell biologists. However, if it is a requirement that stem cells need to be able to flexibly
react to different system needs, it follows that stem cell entities that are restricted to pre-
determined developmental pathways would be extremely inefficient. Furthermore, there is
an increasing amount of data demonstrating that HSCs can flexibly change properties such
as cell surface markers, proliferative activity or repopulation and differentiation efficiency
[27-32].
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In our view, the stem cell hierarchy is a simplified and discrete view of the role an
individual stem cell can take on. It correctly describes the average system behavior on the
level of cell populations but it does not adequately represent the regulatory mechanisms at
the individual cell level. At this level cells with stem cell potential can flexibly and
reversibly switch between different roles within the hierarchy depending on system needs.
Reversibility
Although heterogeneity and flexibility of HSCs are widely accepted, it is still an unresolved
question whether reversibility of functionality and/or phenotype constitutes an essential
mechanism of stem cell organization. From the theoretical side there are strong arguments
for the necessity of at least some degree of reversibility of stem cell properties. If one
assumes that a strict and lossless maintenance of a certain cellular state over time is
impossible, reversibility becomes inevitable to guarantee self-maintaining or even self-
renewing stem cell systems. Again we must revisit the potential vs. behavior view. It is quite
possible that a cell adopts a behavior A, then at a later time a new (possible less stem cell-
like) behavior B and then reverts back to behavior A. In some sense the stem cell behavior
has been reversed. But this may simply be the fact that the cell has potential for both
behaviors A and B and the microenvironment challenges the cell in such a way that behavior
A, then B, then A ensued. So, even though reversibility is observed at the behavior-level, it
has not actually taken place at the level of the cells potential to act.
However, what if the potential of the cell changed? In other words that it had potential to
behave as A or B, then only as B, but then later it regained its potential to behave as either A
or B. It would make sense to say that stem cell potential has been reversed in a very real
sense. The cell has become more ‘stem-like’. Because it is experimentally hard to
demonstrate that a cell’s potential became more stem-like over a specified time (see
discussion above), it is here where the role of theoretical (quantitative) models is critical. It
is models that enable us to systematically investigate (analytically or by simulation) what
happens if potential reversibility is modeled and what happens if it is not. We can’t ever
know the potential of living things but we can of simulated ones, and moreover, the way that
this impacts on the behavior of the entire system.
Asymmetry of stem cell fate
Another point of debate was the occurrence of asymmetries in cellular development.
Although there was no doubt about the necessity and existence of asymmetries in cellular
fate decisions, it is still unresolved as to whether the classical paradigm of an asymmetric
stem cell division is a relevant mechanism in the hematopoietic system. This paradigm –
which sits alongside the fixed discrete stem cell hierarchy – assumes that the division of a
stem cell generates one identical stem cell and one increasingly differentiated cell at some
position lower in the hierarchy. Again, it should be noted that the concept of asymmetric
stem cell division is still the prevalent explanation for a self-renewing population of HSCs,
even though no functionally relevant asymmetries during cell division have been
demonstrated in the hematopoietic system to date.
In a strict sense an asymmetric division mechanism as described above would only allow for
the self-maintenance (in the sense of preserving a population of cells with identical
properties), but not for a true self-renewal [33]. Self-renewal, in the strict sense of the word,
implies the re-gaining of something that had previously been lost. If self-renewal refers to
stem cell numbers, it requires at least the possibility of an expansion of the stem cell
population (such as that which occurs after injury and could arise, for example, by
symmetric division with daughter cells both identical to their mother); if it refers to cellular
properties then it would even require some sort of reversibility in the differentiation process.
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The problem is largely semantic in that the term “self-renewal” is misleading as representing
the concept of self-replication.
If stem cell populations are considered (in contrast to the classical view) as continuous, self-
organizing systems, any division might be seen as asymmetric. This is because even if the
potential of two daughter cells would be identical (which is extremely unlikely in a
continuous world) they would still be occupying different spaces and, therefore, necessarily
not be identical. Thus, any cell division might be considered inherently asymmetric, due to
cumulating small stochastic effects, with the results that both daughter cells will always be
different to the mother cell. Such a perspective (proposed e.g. by Mark Kirkland) would then
necessarily require some degree of reversibility in potential to afford self-renewal as well as
self-maintenance of the population. An alternative concept that has been suggested [34,35]
is that any cell division can a priori be assumed to be symmetric (neglecting small random
differences), with the results of the two daughter cells being identical to the mother cell.
Differentiation (in the sense of changing cellular properties) is considered as an independent
process. This concept of considering cell division and differentiation as (in general)
independent processes would allow a consistent explanation of asymmetries in cell fate
development that occur during the process of cell division (as e.g. reported for epithelial
[36] or neural [37,38] stem cells) as well as of those not linked to cell division events (as e.g.
in the hematopoietic system) within the same conceptual context. See Fig. 1 for illustrations
of the different concepts.
Niche topology
There was consensus about the existence of different types of niches that interact with
HSCs. However, so far there is little information about the dynamics of these interactions.
Do HSCs prefer a particular niche under particular circumstances? Are niche characteristics
fixed or do they change dynamically? Is there competition of HSCs for particular niches?
Data suggest that the most potent HSCs are deeply dormant in a healthy organisms dividing
only very rarely. These dormant cells are distributed as single entities and are often found
directly attached to endosteal osteoblasts in the trabecular bone suggesting that niches may
only house a single stem cell [32]. There is no doubt that stem cell/niche communications
are critical for the control of HSC dormancy and activation on one hand and regulation of
the balance between self-renewal and differentiation on the other. Three-dimensional
modeling of the physical topology of the stem cell/niche unit will be critical to better
understand the complex cell autonomous and non-cell autonomous processes guiding HSC
behavior during homeostasis and injury.
Summary
The predominant views of the workshop were as follows:
1. In referring to, or defining “stem cells” it should be specified if the potential or the
actual behavior is considered as the underlying criterion.
2. Stem cell systems should be considered as self-organizing sets of cells in which
individual behavior is the result of the potential of the cell and the local
environmental conditions. This perspective, however, does not exclude a simplified
description of stem cell systems as structured populations of (dynamically
stabilized) subpopulations of cells at different states if the individual cell level is
not relevant.
3. The microenvironment affects the behavior of cells.
Roeder et al. Page 6
Blood Cells Mol Dis. Author manuscript; available in PMC 2013 August 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. Stem cell niches are probably heterogeneous (for example, osteoblastic and
vascular niche might be different types of niche) – possible continuously so – and
the topology of niches affects behavior.
5. At least some degree of reversibility (of cellular properties/functionalities) is
necessary to achieve true self-renewal within a continuous view of the world.
6. Asymmetries in individual cell fate development should be described by
considering cell division and differentiation as independent processes. This view is
more consistent with the entire range of experimental observations than the
prevailing view of asymmetric division events. However, again the latter
perspective is a possible simplification if considering the cell population level
alone.
7. The range of stem cell potentials and their microenvironments are continuous and
any ‘discrete’ description is necessarily a simplification.
Modeling CML
Mechanisms causing leukemic abnormalities
CML is caused by a t(9;22) chromosomal translocation leading to the formation of the BCR-
ABL oncoprotein. There are a number of molecular processes and signaling pathways,
related to proliferation control, apoptosis regulation, as well as cell adhesion and mobility
that are known to be affected by BCR-ABL (for a review see [39]). It is generally accepted
that as a result of the oncogenic activity, BCR-ABL-positive hematopoietic stem/progenitor
cells can be characterized by one or more of the following properties:
i. an elevated proliferative activity;
ii. a decreased apoptotic activity; and/or
iii. an altered stem cell – microenvironment interaction (e.g. stroma adhesion
behavior).
Key to understanding CML is to know how these properties at the individual cell level affect
the systemic level. It is unresolved as to how the altered individual cell behavior influences
the cell–cell and cell–microenvironment interaction in such a way as to produce the tissue
organization as a multi-cellular phenomenon that we can observe. Furthermore, it is not
known which of the altered cellular properties is the driving force that leads to clonal
expansion and to the malignant overgrowth of the system by leukemic cells. If we knew this,
we would have a better understanding of why treatments worked in the way they did, and
propose improve treatment methods as a result.
During the workshop a number of different possible mechanisms leading to a leukemic
system have been presented and discussed. First, it was suggested that a difference in cell
kinetic properties, such as increased proliferative activity or decreased apoptosis, is not
necessary to explain leukemic expansion. In other words simply item (iii) in the list above
would suffice. Simulation results presented by Janis Abkowitz [40] showed that the use of
additional stem cell supporting niches by BCR-ABL-positive cells would be sufficient to
explain dominance of the leukemic clone in the system. An alternative model, presented by
Ingo Roeder [41], demonstrates that a relative advantage of BCR-ABL-positive HSCs to
utilize available stem cell supporting niches is sufficient to induce an ultimate leukemic
conversion of the system. This model does not require additional niche space. However,
Roeder et al. demonstrated that without the additional assumption of some difference in cell
kinetic properties (such as an enhanced proliferative activity), the clinically observed
increase in total cell production could not be explained. Even though the model results of
Abkowitz et al. and of Roeder et al. both suggest an altered cell–niche interaction as a likely
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mechanism to explain the competitive advantage of the leukemic clone, they do not
(formally) exclude other possible reasons. Though these two speakers propose slightly
different mechanisms, they agree that BCR-ABL-positive HSCs need to exhibit a
competitive advantage relative to the normal cell population to explain the clinical
observations. This result was also substantiated by the mathematical model of CML
proposed by Franzika Michor et al. [43,44]. This model uses differential equations and is
therefore at a higher level of abstraction than the others discussed and so remains neutral
about the mechanisms taking place to induce the growth advantage. However, their results
also demonstrate the necessity for normal HSC homeostasis to be altered for leukemic cells
in such a way that they exhibit a clear competitive advantage over normal cells.
The origin of CML
Another frequently discussed issue at our workshop concerned the origin of leukemic
activity. There was agreement that the development of manifest leukemia requires leukemic
cells to have stem cell potential. In other words, there must be one or a small number of
affected (i.e., mutated) cells that are able to generate a population with sufficient numbers to
maintain leukemic hematopoiesis in the long-term. However, the origin of these initial LSCs
is still under debate.
The most obvious candidate explanation is that the leukemic transformation (i.e. the
induction of a competitive advantage) is induced in the population of HSCs. Alternatively,
another explanation is that cells in more differentiated stages might be mutated and then
(either immediately or later) transformed into a cell type with increased stem cell potential.
Whereas the result – an LSC – is the same in both perspectives, the originating cells might
differ. In fact in a continuous view of the world there is no real qualitative difference
between these views — it would come down to which cells in which environmental
conditions are more or less likely to be transformed. However, in keeping with a more
discrete model perspective it was proposed that we need to distinguish between LSCs and
leukemia-initiating cells. In this view, leukemic stem cells are the result of the initiating
process. The first option is that they are derived from non-stem cells by inducing stem cell
potential together with the leukemic transformation. The second option is that they result
from HSCs by the induction of leukemic properties that do not change their stem cell
potential.
Most theoretical models of CML discussed during the workshop (presented by Janis
Abkowitz [40], Franziska Michor [43-45], Dominik Wordarz [9], Ingo Roeder [41,46] and
Peter Kim [47]) assumed the existence and/or induction of leukemic activity in the HSC
population without considering leukemia induction at other cell stages. The second option
was proposed by Mark Kirkland (unpublished data) who argued that through the disturbance
of the (erythroid) differentiation process, the population of early (erythroid) precursor cells
might experience a dramatic expansion. Kirkland’s model requires a very small probability
of these cells to de-differentiate and become stem cells. He proposes that leukemic
transformation might occur at the level of precursor cells (that is cells that have lost stem
cell potential but are not yet fully differentiated), generating a huge expansion of such cells.
Because there are now so many transformed precursor cells, even though the probability for
any individual cell is very low, there is now a significant system probability for de-
differentiation to take place, which in turn affects the stem cell population.
The question as to whether or not a particular BCR-ABL-generating mutation leads to a
manifest leukemia is impossible to answer in general. It may be the case that there are such
cells in every human that are kept under check, or that it takes only one cell, and some other
specific environmental circumstance, to produce manifest leukemia. Screening data on
healthy volunteers shows that BCR-ABL positive cells can be detected in healthy people,
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even though at a very low frequency [48-50]. Such observations would be consistent with a
stochastic description of CML development as suggested e.g. by Abkowitz et al. or Roeder
et al. Both models predict that the growth advantage induced by the leukemic transformation
would result in an overt leukemia only in a minority of patients because there is a significant
probability of those cells to differentiate or die instead of generating a stable leukemic clone.
Modeling treatment dynamics, residual disease (disease persistence) and treatment
resistant clones
As imatinib treatment currently represents the gold standard for treating CML, this therapy
was also in the focus of the presented modeling approaches. A typical characteristic of the
disease dynamics under imatinib is a bi-phasic decline of BCR-ABL transcript levels (i.e. a
steep decline within the first 6 months of treatment followed by a more attenuated decline),
which is observed in the majority of patients. This dynamic behavior had first been
addressed in a mathematical model proposed by Michor et al. [43] who explained the
imatinib response in CML patients up to one year after treatment start. Later the model
description of the imatinib response had been extended to the description of 5 year follow-
up data [41,51].
Although imatinib (and in general TKI) treatment is able to efficiently reduce the numbers
of leukemic cells in the majority of patients, clinical data show that a considerable amount
of residual leukemic cells can be expected to survive for prolonged times. There are several
candidate mechanisms that can be proposed to be responsible for this persistence:
i. treatment-resistant LSC, either existing before or newly generated after treatment
starts
ii. some LSCs are in a particular state (or microenvironment) that hides them from
treatment
iii. some leukemic cells are not sufficiently in contact with the drug (achieve an
intracellular concentration) for their behavior to be altered
iv. there is a sufficiently high number of leukemic cells each with sufficiently high
BCR-ABL protein levels to neutralize the affects of TKI treatment.
This list suggests we distinguish between residual disease (collection of diseased cells left
after treatment), and selective treatment resistance (specific cells that are not able respond to
treatment). Note that residual disease may or may not include resistant clones.
As shown by long-term follow-up data of patients under imatinib treatment the number of
residual leukemic cells declines slowly for the majority of patients, at least as long as no
treatment resistance occurs. This data provides strong evidence that imatinib treatment
affects the LSC, a conclusion that is supported by different modeling approaches (see [11]
for a review). Although the mechanisms and the degree of this effect are still under
discussion, there was consensus that a certain reduction or at least a decreased expansion of
the LSC pool has to be assumed as a result of the imatinib treatment to explain clinical
observations.
It is also widely accepted that the imatinib effect on LSC spares quiescent (i.e. non-
proliferative) cells [52,53]. This specificity of the treatment effect is most likely one of the
major reasons for the long-term persistence of residual LSC, even without the existence of
definite treatment resistance that would arise through mutations of the ABL kinase domain
of the BCR-ABL protein, for example.
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As a result of the limited sensitivity of current PCR methods, the exact number of residual
leukemic cells is difficult to predict once it has fallen below a certain level (Fig. 2).
Therefore, current estimates of the long-term BCR-ABL dynamics and also of the time to a
potential eradication of all leukemic cells are purely based on model predictions (see e.g.
Roeder et al. [41]) and are still lacking validation by clinical data.
Patient heterogeneity
Although a continuing decline of the BCR-ABL levels over 5 to 7 years could be
demonstrated as an average effect across CML patients, there is a considerable heterogeneity
of this effect among patients. Particularly with respect to treatment decisions after achieving
undetectable BCR-ABL levels, a better understanding of patient specific kinetics is
necessary. Even though in some cases the level of BCR-ABL is undetectable for some years
after stopping treatment [54], we cannot be sure whether or not stopping TKI treatment in
general is a safe option.
As suggested by a simulation study (presentation by Matthias Horn and Ingo Roeder) the
best predictor for the probability of a molecular relapse and the reoccurrence of the disease
after treatment cessation, is the absolute number of residual BCR-ABL positive stem cells.
Because this number is not available from clinical data, it will be important to obtain reliable
estimates for it from other, clinically observable parameters, such as the BCR-ABL decline
kinetics in the blood within individual patients. In this respect, particularly the long-term
BCR-ABL decline kinetics (i.e. the second part of the bi-phasic decline kinetics), is
predictive, because it represents the treatment response of the residual (most likely
quiescent) LSCs. However, there is the hypothesis that also the initial treatment response
(i.e. the BCR-ABL kinetics during the first 6 months after imatinib treatment initiation)
might be predictive for the residual disease kinetics. To test whether or not this hypothesis is
true, a meta-analysis of individual imatinib-response kinetics across different clinical trials
was proposed at the workshop.
Treatment resistance and clonal heterogeneity
Patient heterogeneity can have a number of different determinants. A major factor that has
been extensively discussed is clonal composition, i.e. the existence of subpopulations of
leukemic cells with different growth kinetics and/or treatment sensitivities, generated by the
alteration/mutation of the properties of a single (leukemic) cell that is preserved in its
progeny. Different mechanisms leading to treatment resistance and/or disease persistence
(see above) have been described: e.g. intracellular TKI concentrations due an increased drug
efflux or due to TKI degradation, different levels of the oncoprotein e.g. due to over-
expression and amplification of the BCR-ABL locus, the activation of alternative regulatory
pathways, general pharmacokinetic resistance, and mutations in the ABL kinase domain that
inhibit the binding of TKI molecules (see e.g. [55] and Fig. 3). All these mechanisms might
lead to a heterogeneous composition of the population of leukemic cells with different
degrees of treatment sensitivity.
Some of the mutations in the ABL kinase domain can have severe manifestations with the
result of a complete TKI resistance of these cells. Why and when such resistance mutations
occur is still under debate. Also, the mathematical modeling approaches discussed during
the workshop did not lead to a unique conclusion. Whereas the model presented by Dominik
Wodarz [9,56] suggests that most (if not all) resistance mutations already exist at therapy
initiation, the models proposed by Franziska Michor [43,44] and Ingo Roeder [41,46] lead to
consistent results also for the assumption of resistance mutations that arise after therapy
initiation.
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Another open question in the context of clonal heterogeneity is whether or not the expansion
of a leukemic clone can be affected by other competing clones. For example, there are
reports that the BCR-ABL translocation can be found in a considerable number of healthy
people and there is a sensible hypothesis that a manifest leukemia will only occur in a small
minority of these cases [48,49]. It is currently unclear whether these leukemic clones
disappear because they arise in short-term contributing (e.g. precursor) cells or whether they
are LSCs whose clones might go extinct due to the competition with normal stem cells or
whether they are eliminated by an immune response that fails in the few patients who
develop CML.
Assuming a competition of normal and LSCs, the probability for a manifest leukemia or
similar myeloproliferative disorders arising from a single cell mutation has been estimated
on the basis of model simulation to be in the range of 15% [40] to 20% [41]. If there is a
competition of different clones for common limited resources (such as stem cell supporting
“niches”), this might also explain the dynamic changes in the size of different leukemic
clones under changing treatment. For example, there are observations suggesting that
reducing the size of treatment-sensitive leukemic clones might cause or enhance the
expansion of particular treatment-resistant clones [57]. In the context of clonal competition
such an observation can be explained if one assumes that treatment-sensitive clones are
limiting the expansion of the treatment resistant clones as long as they have a certain critical
size. This limiting competition effect, however, might be lost if the number of treatment-
sensitive cells is reduced sufficiently. To resolve the question as to whether clonal
competition and selection mechanisms can consistently explain the clinical observation and
under which circumstances they might become relevant, will be an important target for
further model analysis.
Treatment options for CML
TKI treatment optimization
Although TKI treatment can be regarded as a highly efficient therapeutic option, treatment
resistance and persistent residual disease still represent major clinical challenges. Beyond
the development and the clinical testing of next generation TKIs, which more efficiently
target the whole spectrum of leukemic clones, the optimization of current TKI treatments is
an important scientific target. It will be necessary to optimize treatment schedules that
combine different TKIs by balancing potential side effects and treatment efficiency.
A second possibility is the combination of TKI treatment with cytokines. One rationale of
such a strategy is based on the observation that imatinib selectively spares quiescent cells.
As suggested by in vitro data [58] and by simulation results [41], the activation of quiescent
LSCs into cell cycle using e.g. the cytokine G-CSF might have the potential to increase the
efficiency of imatinib treatment. However, clinical testing of a sequential application of
imatinib and G-CSF in 28 day cycles (21 days imatinib followed by a 7-day imatinib gap
with 3 pulse doses of G-CSF at days 24, 26 and 28) did not show any advantage of this
combination compared to imatinib alone [42]. Although this result seems at first glance to be
discouraging, simulation studies based on the model proposed by Roeder et al. (unpublished
data, presented at the workshop by Matthias Horn) show that the predicted beneficial effect
depends on the application schedule: the model predicts that it is strongest for a
simultaneous application of the proliferation activating cytokine and imatinib but it is almost
lost for a sequential application of imatinib and G-CSF. Critically, the pilot trial contained
exactly such a sequential application. Therefore, it still needs to be resolved as to why a
simultaneous application of G-CSF and imatinib did not show any effect in the in vitro
setting, which motivated the clinical trial and whether the predicted benefit of a
simultaneous application can be achieved in vivo.
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Another promising option is the combination of TKI and interferon (IFN)-α treatment.
Chronic treatment of IFN-α has a negative effect on the self-renewal capacity of mouse
HSCs in vivo, acute IFN-α treatment results in the very effective activation of dormant
HSCs. Most interestingly, IFN-α activated HSCs show a dramatically increased sensitivity
to anti-proliferative chemotherapy mediated killing [59]. Although it remains to be shown
whether human HSCs or LSCs behave similarly, these results open the possibility that in a
scheme similar to the one mentioned above for G-CSF, IFN-α may be used to activate,
dormant CML stem cells and thus sensitize (“prime”) them to imatinib mediated
elimination. In agreement with this hypothesis, some patients initially treated with IFN-α
but subsequently switched to imatinib (due to the change in the treatment protocol) showed
a surprisingly high rate of long-term complete remission (>2 years) [59]. These data suggest
that the cooperative effect of IFN-α “priming” with imatinib may create a possibility to
target the CML-stem cell.
Alternative drug treatment
As quiescent LSCs are able to “hide themselves” or be insensitive in some other way to TKI
treatment, the use of compounds that are able to target specifically this population of cells
obviously suggests an alternative approach. BMS-214662, a cytotoxic farnesyltransferase
inhibitor that was reported to kill non-proliferating tumor cells, has been suggested as a
potential compound for an effective treatment of CML [60]. BMS-214662, alone or in
combination with imatinib or dasatinib, was shown to induce apoptosis of both proliferating
and quiescent leukemic stem-progenitor cells in vitro whereas normal stem-progenitor cells
were relatively unaffected. Although these results still need to be consolidated, a selective
apoptosis induction in quiescent LSCs can be expected to enhance the reduction of residual
LSCs.
Immunotherapy
The potential cure of CML patients by allogeneic stem cell transplantation relies to a
considerable degree on the graft-versus-leukemia effect, which consists of the
immunological recognition of antigens on residual leukemia cells by donor T lymphocytes.
The idea of immunotherapeutic approaches is to take advantage of a similar effect for
patients who do not receive a stem cell transplantation, applying vaccines which target
leukemia-specific or leukemia-associated antigens to eradicate residual leukemic cells.
Although, targeting leukemia-specific BCR-ABL peptide vaccines did not show the
expected efficiency (Michael Deininger, unpublished data), peptide vaccines targeting
leukemia-associated antigens which are overexpressed in CML cells (e.g. WT1 and PR1,
derived from Wilm’s tumor-1, and proteinase 3 and elastase proteins, respectively) have
been shown to be efficacious and safe [61-63]. In order to more efficiently target residual
disease in the majority of chronic phase CML patients currently treated with TKIs, a
combination vaccine of WT1 and PR1 peptides is suggested as this has the ability to target
both primitive and mature CML progenitors [64]. Despite these experimental results that
clearly point to the general potential of immunotherapeutic approaches in CML treatment, it
is also the case that current mathematical models predict the potential of vaccination to
ameliorate the therapeutic outcome of TKI treatments. Based on the clinical data, showing
that there is an inherent immune response in a considerable part of imatinib-treated CML
patients [65], Kim et al. [66] investigated the dynamic system response of a vaccination in
these patients using a revised version of the mathematical CML model proposed by Michor
et al. [43]. Their simulation results demonstrate that vaccination (using inactivated CML
cells) might be able to amplify the inherent immune response and to drive the residual LSCs
into extinction.
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On quantitative modeling
Quantitative (mathematical) models help us – sometimes in an abstract way – to understand
the nature of things that we observe. But there are some key properties of models that often
go overlooked and it is worth enumerating them here. Our main purpose within this section
is to increase the role and significance of modeling in the view of those who traditionally
have not used models. We therefore provide a list of issues that should be considered when
developing models with a view to encouraging interdisciplinary collaboration and gaining
the “buy in” of clinicians.
1. Models are always a simplification of the (physical) world they represent.
However, simplification and abstraction is often the key to understanding generic
principles and thus providing biological insights.
2. Models are artificial, and whilst we have ways of tying them with reality (such as
falsification) they can never have the same reality as experiments. Nevertheless,
they can identify inconsistencies in experimental data and/or their interpretations.
3. Models always encode assumptions about the world, and any implicit assumptions
should always be made sufficiently clear. Also, it should be made clear how the
model “copes” when any of these assumptions are relaxed.
4. There is no unique (“best”) model for a particular problem. Therefore, for any
model its assumptions, its scope, its limitations, and its significance to
experimentalists should clearly be outlined.
5. A model is always caged in particular mathematical method, and any method has
advantages and disadvantages over other mathematical methods.
6. Models should demonstrate consistency with real sets of data and, furthermore,
point to new experiments to determine possibly unexplored or undetermined
potential behaviors. In other words, models should be testable and predictive.
7. Models should be flexible and extensible allowing new ideas, concepts and theories
to be incorporated.
Beyond fitting data and proposing testable predictions, modeling has a role in proposing
new hypotheses and, therefore, in changing commonly held out-dated views. This is
particularly true for the demonstration of inconsistencies of “old” paradigms as well as for
providing alternative explanations. With respect to stem cell biology, we think that
mathematical models (including those presented at the workshop) will help to resolve
general inconsistencies in explaining e.g. the hierarchical appearance of stem and progenitor
cell populations on the one hand and the observed flexibility and reversibility of stem cell
functionality on the other hand. One way to achieve this is to describe stem cell populations
as dynamical (self-organizing) systems, rather than as fixed, pre-determined structures.
As outlined above, there is no unique model representation of a biological process. In this
respect it is interesting to note that several of the models (discussed at the workshop) use
different ways to describe cellular development in the hematopoietic system. Some
approaches comprise four distinguishable cell types (stem, progenitor, precursors and
mature; e.g. Michor, Kim), whereas others consider only stem and non-stem cells with a
structured stem cell population (e.g. Roeder) or even a complete continuum of cells with
varying stemness potential (e.g. Kirkland). To compare these approaches, it is necessary to,
firstly, be very clear about language (e.g., what defines stem, progenitor, precursor or mature
cells) and to, secondly, outline the scope of the particular model. We have discussed the
definition of stem cells in previous sections. Progenitor cells are cells that can be isolated
from hematopoietic tissue (marrow) and grown in various culture systems as clonal colonies
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but that lack long-term in vivo repopulating ability. Whereas multipotential progenitors can
undergo differentiation into several lineages (as judged by the presence for example of
megakaryocytes, neutrophils, and erythrocytes in the colony), unilineage progenitors can
generate only a single lineage (e.g. erythrocytes or neutrophils or monocytes, etc). In
contrast to the more primitive progenitors, precursor cells can be identified by light
microscopy of marrow and their kinetic behavior has been described in extenso. For
example, they range from proerythroblasts to orthochromatic erythroblasts, myeloblasts to
band neutrophils, etc. Mature blood cells are self-evident.
Whereas heterogeneity of hematopoietic cells is represented in terms of subpopulations by
some of the models, it is described by continuously varying cellular properties by others.
None of these descriptions claims to be exclusive, but they focus on different aspects and
one way to understand general biological principles is to identify those bits and pieces of the
different model descriptions which represent conceptual differences and are not simply
alternative ways of a mathematical representation. One candidate of such a “generic”
principle is reversibility of stem cell properties.
Also with respect to the applied mathematical methodology the presented models differ; two
dominant modeling strategies arose: The first of these uses deterministic differential
equations and gives a high level analysis of the global properties of a stem cell system
[43,44,47,66]. Such models are attractive as they can be tuned to fit data at the cell
population level and because they are reasonably straightforward to specify. Such a
representation of stem cell populations approximates the system behavior by describing the
“average” behavior of cells. That is to say, these models are correct at the cell population
level, but cannot describe individual cell fates. The second general class of methods includes
stochastic processes into the description. Although there are different roles for stochastic
components in mathematical models, they are essentially placeholders for where we do not
have enough information to model the specific physical (and specifically causal) processes
that are taking place. In contrast to the above mentioned deterministic differential equation
models, they allow for a description of the heterogeneity within cell populations. Whereas
some of the stochastic approaches are acting at the cell population level [40,56,67], others
are explicitly modeling the fate of individual cells and allowing for a representation of the
clonal relationship of all cells within the system [41,68].
Stochastic representations, as they have been applied here, stand for an approximation of
complex cellular and molecular interactions. However, as we gain further information about
the subject we are modeling, we may begin to model our cells and their environments in
more detail. As we do, we can start to remove stochastic approximations and to model the
internal state of the cells and the external environment by (simple) physical or chemical
mechanisms. This relatively new method of modeling complex systems is known as an
agent-based modeling [69]. The advantages of this approach are that we can begin to
investigate how specific chemical and spatial mechanisms at the level of individual cell
behavior can affect the system behavior and that they are not biased by any mathematical
technique [70]. Agent-based modeling is a specific approach to thinking about dynamic
systems, one that combines simple mechanisms with computational processing to generate
complex outcomes or phenomena. Moreover, in situations where individual components
within a living system cannot be observed without damage or change to those components
(such as changing the environment), the agent method allows one to work in simulation,
with precise observation of experiments at multiple levels, something currently unachievable
in wet-lab experiments. In years to come it seems clear that this approach will increase in
popularity.
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Thus, it is difficult to say what makes a good model in any general sense, but important
issues definitely include simplicity so it can be analyzed and understood, clarity so that the
assumptions are made clear, accurateness so that it matches data, computability so that we
can simulate complexity, flexibility so that it can be applied to more than one set of
experiments, robustness in that small perturbations do not impact catastrophically on self-
organization, and testability such that the model can be validated/falsified by comparison
with real data. Also, it should be emphasized again that models are always hypotheses (even
if they consistently describe real data) and that different modeling approaches are often
promoting conflicting perspectives. However, these facts do not disqualify models as serious
scientific tools. In contrast, it is one of the strengths of mathematical models that they allow
us to investigate, test, and compare different alternative hypotheses. In particular, the
investigation of alternative perspectives is vital for the scientific process to arrive at a more
comprehensive understanding of complex biological processes.
A summary and the way forward for CML research
From the workshop discussions two leading, clinically relevant, questions emerged. First, is
there a predictable time of cure under current TKI treatment scenarios? Second, what is the
optimal strategy to target LSCs? Further open questions that were discussed on the basis of
the presented concepts were the origin of CML, the resistance dynamics and mutation
evolution of cells, models of treatment dynamics, as well as making predictions of new
treatment options for CML. Conceptual assumptions that were under debate could be listed
as follows:
1. Is the concept of reversibility of stem cell properties/functionality necessary?
2. Do we have to distinguish between progenitor and stem cells, as the target cell
population (leukemia-initiating cells) for leukemic mutation events?
3. What differences of leukemic and normal stem cells have to be assumed? Is there a
cell specific growth advantage or disadvantage and/or is there a competition for
resources, such as niche space?
4. Should the cell kinetic status of leukemic (stem) cells be considered as a relevant
factor effecting treatment efficiency?
There was agreement that besides their application in identifying general mechanisms of
disease development and therapeutic effects, a major potential of modeling approaches in
the field of leukemia research is their application with respect to the design of optimized
treatment schedules, including the model-based design of clinical trials. As demonstrated
during the workshop, this is not only a potential option for the future, but it is a tool which is
available right now as we have mathematical models available that already provide
qualitative ideas as well as tangible quantitative predictions for particular treatment
scenarios (e.g. [41,43-44,47,68]).
There are a number of issues, identified during the workshop that should be investigated
(experimentally and theoretically) in the future. One important field is a better understanding
of clonal competition effects between different (leukemic) stem cell clones. Furthermore, it
became clear that immunological effects should not be neglected in the modeling
approaches because they might sensitively affect the clonal dynamics of leukemic cells. We
also identified the need for a better characterization and understanding of the property
differences between normal and LSCs. As the knowledge of cellular parameters (e.g.
proliferative activity or chemosensitivity) has considerable effects on the choice of model
assumptions and, therefore, on the predicted system dynamics, it would be preferable if
experimental studies were planned in close collaboration of experimentalist and modelers to
ensure the correct determination of most relevant and informative parameters. This similarly
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applies to clinical investigations. The workshop demonstrated the potential that theoretical
methods can have in predicting possible quantitative effects that might be expected under
certain conditions, and it is increasingly the case that model analyses and simulation studies
should be taken into account as an additional/complementary means when designing clinical
trials.
Arguably the greatest success of this workshop was to bring clinicians, experimentalists and
modelers together. Clinicians and experimentalist are beginning to realize the value that
theoretical models can contribute to the understanding of biological processes and to the
optimization of therapeutic strategies. On the other hand, modelers gained a better insight
into practical problems and constraints of experimental and clinical investigations. We
believe that this workshop has contributed to paving the way to more fruitful synergy in the
future modeling of CML.
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Fig. 1.
Concepts of stem cell fate asymmetry. Unfilled circles: stem cells; Filled circles:
Differentiated cells (different grey levels illustrate different degrees of differentiation) (A)
Strictly asymmetric stem cell division at the individual cell level. (B) Two options of
(strictly) symmetric types of cell division at the individual cell level, which allows an
explanation for asymmetric stem cell fate at the population level. (C – E) Assumption of a
cell cycle independent differentiation process. (C) Assumption of an inevitable (small,
stochastic) asymmetry in every cell division. Differentiation process assumed to be
reversible, which allows for self-maintenance (or self-renewal) of stem cell state and of
continued differentiation. (D, E) Assumption of strictly symmetric cell divisions (potentially
as approximating small, stochastic differences) (D) Differentiation independent of cell
division but irreversible (only self-maintenance of a cellular state but no self-renewal
possible). (E) Differentiation independent of cell division but potentially reversible (both
self-maintenance and self-renewal of a cellular state possible).
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Fig. 2.
Relationship of absolute number of leukemic cells and BCR-ABL transcript levels (adopted
from a scheme provided by Junia Melo.)
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Fig. 3.
Mechanisms of imatinib mesylate resistance (adopted from a scheme provided by Tessa
Holyoake). The scheme shown a collection of mechanisms that have been suggested as to
potentially inducing resistance of leukemic cells to imatinib mesylate treatment.
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